China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

China SXT Pharmaceutical is a holding company that conducts its business through subsidiaries and a variable interest entity in China. The company focuses on the research development manufacture marketing and sale of traditional Chinese medicine products. Its core operations are carried out by the variable interest entity Taizhou Suxuantang which produces and sells three categories of TCMP products. China SXT Pharmaceutical was incorporated in the British Virgin Islands on July 4 2017 and its wholly owned subsidiary SXT HK was incorporated in Hong Kong on July 21 2017. The principal executive offices are located at 178 Taidong Rd North Taizhou Jiangsu PRC and the corporate website is www sxtchina com. The company operates under the legal framework of the Peoples Republic of China and is subject to regulations governing foreign invested enterprises and traditional Chinese medicine manufacturing.

Revenue is generated primarily from the sale of Advanced TCMP Fine TCMP and Regular TCMP products as well as raw medicinal materials. Advanced TCMP includes directly oral and after soaking formulations and contributed 49 point 1 percent of total revenue for the fiscal year ended March 31 2024. Regular TCMP represented 49 point 0 percent of revenue in the same period while Fine TCMP accounted for the remaining share. The company also derives income from the sale of raw materials used in the production process. Products are sold to hospitals especially traditional Chinese medicine hospitals pharmaceutical distributors and chain pharmacies across several provinces. In recent fiscal years revenue has shown modest fluctuations with a slight decrease from 2023 to 2024.

China SXT Pharmaceutical competes with other established manufacturers of traditional Chinese medicine in China such as Kangmei CTCM and Xiangxue. The company holds a competitive advantage through its well known brand Suxuantang which has more than two hundred seventy years of history and is recognized across eastern China. Its ready to use TCMP formulations eliminate the need for decoction giving it an edge over peers. Additionally the firm possesses the required pharmaceutical manufacturing permits and GMP certificates for its product lines and benefits from a strong research and development team that has produced multiple patent applications. The management team possesses extensive experience in the traditional Chinese medicine industry and has built an integrated production sales and distribution network. The company pursues growth by expanding its product portfolio strengthening its brand recognition and broadening its domestic and international distribution channels.

The company serves hospitals particularly traditional Chinese medicine hospitals primarily in Jiangsu province as well as pharmaceutical distributors and chain pharmacies. As of March 31 2024 the end customer base comprised 57 pharmaceutical companies 14 chain pharmacies and 16 hospitals located in Jiangsu Anhui Jiangxi Guangdong and Hubei. China SXT Pharmaceutical maintains four sales offices covering twelve provinces and municipalities including Jiangsu Hubei Shandong Liaoning Anhui Henan Jiangxi Guangdong Chongqing Sichuan Hebei and Fujian. Over sixty eight sales representatives support the distribution network and relationships with suppliers. The firm sources raw materials from long term suppliers in Anhui Jiangsu Jiangxi Sichuan and Hebei provinces ensuring a stable supply of authentic traditional Chinese medicine ingredients.